Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ambitions of leading multinational companies for a long-term positioning in India through acquisition of generic companies may face rigid policy restrictions from a government concerned about monopoly-dictated pricing for needed drugs
You may also be interested in...
India Maintains Status Quo On Compulsory Licensing Provisions
Indian generics industry, multi-national company lobbies welcome moves to keep flexibility, but doubts linger regarding future investments.
India Maintains Status Quo On Compulsory Licensing Provisions
Indian generics industry, multi-national company lobbies welcome moves to keep flexibility, but doubts linger regarding future investments.
India Maintains Status Quo On Compulsory Licensing Provisions; Indian, MNC Lobbies Welcome Moves To Keep Flexibility But Future Doubts Linger
MUMBAI - Lobby groups from both the Indian generics industry and multinational companies hailed a decision by the Indian government to maintain the status quo on legal provisions that determine the conditions needed to trigger a compulsory license for a drug. But both sides expressed apprehension on how the present set of norms will unfold, fearing that future investments or market opportunities may be at risk if wrong moves are made
Need a specific report? 1000+ reports available
Buy Reports